The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Net loss | -359,639 | -109,963 | -85,895 | -68,867 |
| Amortization of investment premiums | - | - | - | 1,217 |
| (accretion) amortization of investment premiums | 9,284 | 17,267 | 8,202 | - |
| Amortization of financing costs | 56 | 94 | 88 | 59 |
| Stock-based compensation | 40,818 | 29,712 | 16,750 | 8,673 |
| Amortization of right-of-use assets | 431 | 346 | 292 | 291 |
| Realized gain on investment | 55 | 112 | - | - |
| Interest expense related to operating lease liability | 10 | 38 | 43 | 41 |
| Prepaid expenses and other current assets | 5,199 | -446 | -6,408 | 3,130 |
| Accrued interest, net of interest receivable on maturity of investments | -5,076 | -1,199 | -321 | -614 |
| Accounts payable | 43,438 | 2,303 | -1,018 | 7,085 |
| Accrued expenses | 6,168 | 5,816 | -1,816 | 5,809 |
| Lease liability | -505 | -402 | -347 | -189 |
| Net cash used in operating activities | -278,685 | -87,790 | -73,376 | -48,397 |
| Purchases of investments | 418,037 | 1,113,368 | 478,303 | 121,431 |
| Proceeds from sales and maturities of investments | 759,425 | 560,002 | 299,217 | 176,184 |
| Net cash (used in) provided by investing activities | 341,388 | -553,366 | -179,086 | 54,753 |
| Public offering and financing costs | - | - | - | 22 |
| Public offering, net of offering costs | 0 | -597,094 | -269,760 | - |
| Value of shares withheld related to employee tax withholding | 0 | 42,101 | 7,121 | 1,533 |
| Repurchase of common stock | - | - | - | 6,795 |
| Proceeds from warrant and option exercises and stock issuances under employee stock purchase plan | 2,491 | 10,813 | 6,768 | 848 |
| Atm offering, net of fees | 73,948 | 46,658 | 1,969 | 11,665 |
| Net cash provided by financing activities | 76,439 | 612,464 | 271,376 | 4,163 |
| Net (decrease) increase in cash and cash equivalents | 139,142 | -28,692 | 18,914 | - |
| Cash and cash equivalents at beginning of period | 26,676 | 55,516 | 36,632 | - |
| Effect of exchange rate changes on cash | -8 | -148 | -30 | - |
| Net increase (decrease) in cash and cash equivalents | - | - | - | 10,519 |
| Cash and cash equivalents at end of period | 165,810 | 26,676 | 55,516 | - |
Viking Therapeutics, Inc. (VKTX)
Viking Therapeutics, Inc. (VKTX)